US2018057575A1PendingUtilityA1

COMPOSITIONS AND METHODS OF USE FOR DETERMINATION OF HE4a

50
Assignee: PACIFIC NORTHWEST DIABETES RES INSTITUTEPriority: Feb 17, 2011Filed: Oct 19, 2017Published: Mar 1, 2018
Est. expiryFeb 17, 2031(~4.6 yrs left)· nominal 20-yr term from priority
Inventors:Ingegerd HellstromKarl E. HellstromJohn RaycraftChristian FermérEva Röijer
G01N 33/57545G01N 33/5755G01N 2800/52C07K 16/18C07K 16/3069C07K 14/435A61K 39/395A61K 38/18A61K 48/00C07K 16/28C07K 16/24A61K 38/17C07K 14/475C07K 2317/14C07K 16/22A61K 38/19G01N 33/575G01N 33/57411G01N 33/57449C07K 16/30
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention includes the use of the HE/HE4a markers to assess ovarian cancer in a subject. Included also are compositions and methods of using HE/HE4a marker for diagnosis, grading and staging of ovarian cancers, determining prognosis and treatment effectiveness of a subject who has been diagnosed with ovarian cancer.

Claims

exact text as granted — not AI-modified
1 . A monoclonal antibody capable of specifically binding to HE4a, wherein the antibody is selected from the group consisting of:
 (a) the monoclonal antibody produced by the hybridoma cell line 12A2, deposited with the ECACC as Patent Deposit No. 10091401.   (b) the monoclonal antibody produced by the hybridoma cell line 14E2, deposited with the ECACC as Patent Deposit No. 11022202.   (c) a monoclonal antibody that binds to the amino acid sequence set forth in SEQ ID NO: HE4a N-WFDC;   (d) a monoclonal antibody that is an antigen binding fragment of a monoclonal antibody of (a)-(c), wherein the fragment retains the capability of specifically binding to HE4a.   
     
     
         2 .- 57 . (canceled)

Join the waitlist — get patent alerts

Track US2018057575A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.